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Abstract
Background: Activation of the transcription factor NF-kB by cytokines is rapid, mediated through the activation of the IKK
complex with subsequent phosphorylation and degradation of the inhibitory IkB proteins. The IKK complex is comprised of
two catalytic subunits, IKKa and IKKb, and a regulatory protein known as NEMO. Using cells from mice that are genetically
deficient in IKKb or IKKa, or using a kinase inactive mutant of IKKb, it has been proposed that IKKb is critical for TNF-induced
IkB phosphorylation/degradation through the canonical pathway while IKKa has been shown to be involved in the non-
canonical pathway for NF-kB activation. These conclusions have led to a focus on development of IKKb inhibitors for
potential use in inflammatory disorders and cancer.
Methodology: Analysis of NF-kB activation in response to TNF in MEFs reveals that IKKb is essential for efficient
phosphorylation and subsequent degradation of IkBa, yet IKKa contributes to the NF-kB activation response in these cells
as measured via DNA binding assays. In HeLa cells, both IKKa and IKKb contribute to IkBa phosphorylation and NF-kB
activation. A kinase inactive mutant of IKKb, which has been used as evidence for the critical importance of IKKb in TNF-
induced signaling, blocks activation of NF-kB induced by IKKa, even in cells that are deficient in IKKb.
Conclusions: These results demonstrate the importance of IKKa in canonical NF-kB activation, downstream of cytokine
treatment of cells. The experiments suggest that IKKa will be a therapeutic target in inflammatory disorders.
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Introduction
The transcription factor nuclear factor-kappaB (NF-kB)
plays critical roles in inflammation, control of cell death
pathways and cell proliferation which are hallmarks of many
human diseases [1–3]. The mammalian NF-kB transcription
factor is a family of 5 proteins comprised of NF-kB1 (p50/
p105), NF-kB2 (p52/p100), c-Rel, RelB, and RelA (p65).
These proteins exist as homo- or heterodimers bound by
inhibitory kB( I kB) proteins under unstimulated conditions [3].
In unstimulated cells, NF-kB is tightly regulated by one of
several inhibitors of NF-kB( I kBa, b, e) [1–4]. A large number
of intra- and extra-cellular stimuli, including cytokines, PMA,
bacterial LPS, viral infection, stress-induced responses, and T
and B cell activation, lead to NF-kB activation. NF-kB
activation involves IkBk i n a s e( I K K )a c t i v a t i o nw h i c hl e a d s
to IkB phosphorylation and subsequent ubiquitin-dependent
IkB degradation by the 26S proteosome complex [1–4]. The
released NF-kB transcription factor with unmasked nuclear
localization signal then accumulates in the nucleus to regulate
the expression of genes encoding cytokines, cytokine receptors,
and apoptotic regulators [1–4].
IkB phosphorylation by the high molecular weight IkB kinase
(IKK) complex (approximately 700 kDa) is a critical regulatory
step in the NF-kB activation pathway [1–5]. This kinase complex
was partially identified initially in unstimulated Hela cells and was
later found to be activated in cells treated with TNFa [6].
Subsequently several groups identified two highly related kinases
named IKK1/IKKa and IKK2/IKKb as the catalytic compo-
nents of this complex [6–8]. Both of these kinases have been shown
to have specificity for serines 32 and 36 in the N-terminus of IkBa
with phosphorylation leading to ubiquitination and degradation of
this inhibitory protein [9]. In addition to IKKa and IKKb, a non-
catalytic, regulatory component of IKK was also identified and
called NF-kB Essential modifier (NEMO) or IKKc [10,11].
Additionally, it has been reported that both IKKa and IKKb can
phosphorylate the RelA/p65 subunit to promote transactivation
potential [12].
Insight into the physiological roles of the two catalytic IKK
subunits comes from gene targeting studies. IKKb knockout mice
display a phenotype similar or identical to knockout of RelA,
namely embryonic lethal with severe liver apoptosis [13–15]. A
similar phenotype was seen in the NEMO/IKKc knockout animal
[16]. Mouse embryonic fibroblast cells that were isolated from
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and interleukin-1alpha-induced NF-kB activity, as measured by
EMSA and by effects on IkB degradation. The IKKb 2/2
knockout cells exhibit significantly enhanced apoptosis in response
to TNFa [13–15]. Importantly, IKK activity directed to
phosphorylation of IkB in vitro was essentially lost in IKKb null
cells [13–15]. A role of IKKa in classical NF-kB signaling is less
clear compared to IKKb. IKKa deficient mice exhibit abnormal
morphogenesis and developmental defects [17–19]. Consistent
with conclusions derived using IKKb 2/2 fibroblasts, IKKa does
not seem to have a significant influence on cytokine-induced IKK
activity directed to IkBa [17,18]. However, IKKa-deficient mouse
embryonic fibroblast (MEF) cells exhibited reduced NF-kB
activation as measured by EMSA in response to cytokine
treatment [17,18]. Another group did not find reduced cytokine-
induced NF-kB DNA binding activity in IKKa 2/2 MEFs [19].
In the light of these genetic studies and additional biochemical
studies, it has been generally assumed that IKKb but not IKKa is
the primary regulator of NF-kB dependent proinflammatory
signal transduction [1–5]. On the other hand, IKKa is known to
be essential in non-canonical NF-kB activation by regulating p100
precursor processing and activation of the p52/RelB heterodimer
[1–5]. Recently, we and others have demonstrated that IKKa has
an important nuclear function by regulating the control of target
genes at the level of histone phosphorylation [20,21]. Interestingly,
the observation that hepatocyte-specific ablation of IKKb did not
lead to impaired activation of NF-kB by TNF as measured by gel
shift assay and IkB degradation [22] suggests the involvement of
another kinase in the canonical pathway at least in adult
hepatocytes. Here we have explored individual roles of IKKa
and IKKb in canonical NF-kB activation in MEF cells as well as
cancer cells. Our results suggest that IKKa, like IKKb, is critical
for efficient cytokine-induced NF-kB activation. In fibroblasts
IKKa is not significantly involved in IkBa phosphorylation/
degradation, yet contributes to activation of NF-kB through an
unknown mechanism in these cells. In HeLa cells, IKKa and
IKKb each contribute to IKK activity directed to IkBa to control
its phosphorylation and subsequent degradation. Expression of a
kinase inactive variant of IKKb, which has been used previously to
provide evidence for the importance of IKKb in the canonical
pathway, is shown here to block IKKa activity. These studies
suggest that inhibition of IKKa is a rational approach in blocking
inflammatory disorders.
Materials and Methods
Reagents and Materials
Mouse embryonic fibroblast (MEF) and HeLa cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM),
complemented with 10% fetal calf serum (FCS), 100 units/ml
penicillin, 100 mg/ml streptomycin. SKBr3 cells were cultured in
McCoy’s 5A medium complemented with 10% fetal calf serum
(FCS), 100 units/ml penicillin and 100 mg/ml streptomycin. Wild
type, IKKa, IKKb single and IKKa/b double knockout cells
(DKO) were the kind gift from Dr. Inder Verma. Antibodies to
phospho-specific NF-kB p65 (Ser-536) and IkBa (Ser 32/36) were
obtained from Cell Signaling. Antibodies to b-tubulin and to IkBa
were obtained from Santa Cruz. Antibodies to IKKa and IKKb
were obtained from Upstate Biotechnology Inc. RhTNF-a
(Promega) was used at a final concentration of 10 ng/ml.
Western Blot
After stimulation, cultured cells were lysed on ice for 5 min in
RIPA lysis buffer with freshly added protease and phosphatase
inhibitor cocktails. Lysates were cleared by centrifugation at 4 uC
for 15 min at 13,000 g. The amount of total protein was measured
and equal amounts (20 mg) were fractionated by NuPAGE Novex
4–12% Bis Tris gels (Invitrogen) and electro-transferred to
polyvinylidene difluoride membranes. Membranes were blotted
with the indicated antibodies, and proteins were detected using an
enhanced chemiluminescence detection system (Amersham Bio-
sciences, Freiburg, Germany). Where indicated, membranes were
stripped and re-probed with the indicated antibody.
Electrophoretic Mobility Shift Assay (EMSA)
EMSAs were performed as previously described [23]. Briefly,
425 mg of nuclear extracts, prepared following cell stimulation, were
incubated with a radiolabeled DNA probe containing an NF-kB
consensus site. For supershifts, 1 ml of anti-p65 antibody (Rockland)
or 2 ml of anti-p50 antibody (Santa Cruz, SC-7178) was added and
thebindingreaction wasallowed toproceed for an additional 15 min.
Protein2DNA complexes were resolved on a non-denaturing
polyacrylamide gel and visualized by autoradiography.
siRNA Knockdown Experiments
IKKa and IKKb mRNA were knocked down with siRNA
obtained from Dharmacon. Dharmafect 1 (Dharmacon Company)
transfection reagent was used for all si-RNA transfection as
described in the manufacturer’s protocol. SiRNA was transfected
for 72 hrs, and lysate preparation and westerns were performed as
described [24].
Luciferase Assays
SKBr3 cells stably expressing the 3x-kB plasmid were plated in
equal number in triplicate in 24-well plates and transfected with
siRNA for 72 hours. Cells were lysed in MPER and luciferase
activity was measured with Promega Luciferase Assay System
(Promega). Luciferase levels were normalized by protein concen-
tration using a Bradford assay. MEF cells were seeded in 24-well
plates at 30–50% density and transfected the next day with the
indicated expression vectors and 3x-kB Luciferase reporter gene
for 48 h using Effectene (Qiagen) transfection reagent according to
the manufacturer’s instruction. b-galactosidase reporter gene was
used as an internal control. The total amount of transfected DNA
(500 ng of DNA) in each well was adjusted by adding empty
plasmid vector (pcDNA3.1). Where indicated, 100 ng and 200 ng
of IKKb KM vector has been used. Luciferase activity of whole
cell lysates was measured by using a luciferase assay kit (Promega).
b-galactosidase activity was measured by liquid -galactosidase
assay with chlorophenolred-b-D-galactopyranoside substrate. Rel-
ative luciferase activity was calculated by normalizing the assay
results to b-galactosidase expression values. Luciferase-fold
induction was calculated by normalizing the results to control
treatment, which was assumed as 1-fold induction. HeLa cells,
seeded in 24-well plates were transiently transfected with the
indicated siRNAs for 48 hr. Media was then replaced and cells
were further transfected with the NF-kB response 3X-kB
luciferase reporter and a control Renilla luciferase construct.
24 hr later, cells were lysed and dual luciferase assays were
performed. Luciferase readings in untreated and control vector
transfected cells were normalized to 1.
Results
TNF-Induced NF-kB Activity Is Diminished in IKKa as Well
as IKKb Deficient MEF Cells
Experiments were initiated to assay roles of IKKa and IKKb in
inducing IkBa phosphorylation and activation of NF-kBi n
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purpose, mouse embryonic fibroblast cells (MEFs) that are
deficient for IKKa or for IKKb singly as well as IKKa/b double
knock-out cells have been utilized. As shown in Figure 1, TNFa
induces expected p65 phosphorylation at Ser 536 position as well
as IkBa degradation in as early as 5 minutes post-stimulation.
Importantly, there is diminished p65 phosphorylation in both
IKKa and IKKb deficient MEF cells. Interestingly, lack of IKKa
delayed IkBa degradation while lack of IKKb significantly
suppressed the TNF-induced degradation of IkBa. Relative to
the IKKb deficient cells, IkBa appears weakly degraded at the 30
minute time point (Fig. 1) but by 60 minutes these levels return
(data not shown, and also see ref. 15). IKKa/b DKO MEFs have
near complete loss of p65 phosphorylation and IkBa degradation,
as expected (note lower levels of IkBa in these cells, indicating
significantly reduced NF-kB-dependent transcription of its inhib-
itor). These results (Figure 1) demonstrate that both IKKa and
IKKb are required for efficient NF-kB activation in MEFs as
measured by p65 phosphorylation at Ser536, yet IKKb appears to
be significantly more important in the IkBa phosphorylation/
degradation response in fibroblasts. This work is consistent with
previous work [13–15,17–19] which showed that IKK in vitro
activity, directed to recombinant IkBa, is not diminished in IKK1
(IKKa) null MEFs, yet is significantly reduced in IKK2/IKKb
null cells.
NF-kB DNA Binding Activity Is Diminished in both IKKa
and IKKb Deficient MEF Cells
In addition to IkBa degradation and p65 phosphorylation, we
have studied whether IKKa and IKKb differentially affect NF-kB
DNA binding activity in response to TNF as measured by EMSA/
gel shift assay. NF-kB DNA binding activity was investigated in
WT, IKKa 2/2, and IKKb 2/2 cells. As shown in Figure 2,
there is significant induction of NF-kB (p50/p65) DNA binding
activity in response to TNFa in WT MEF cells. However, this
DNA binding activity is diminished in both IKKa and IKKb
deficient cells. The level and the kinetics of NF-kB DNA binding
activity is comparable in IKKa and IKKb deficient MEFs cells.
This data suggests that IKKa, as well IKKb, is essential for
optimal NF-kB DNA binding activity, potentially through
different mechanisms (see Discussion). Promoter studies (see
below) confirm a functional role for IKKa in TNF-induced NF-
kB activation in MEF cells.
Similar Roles for IKKa and IKKb in Response to TNFa
Induced NF-kB Activation in Hela Cells
Most studies regarding the roles of IKKa and IKKb have been
performed in MEFs null for either subunit. To expand these
studies, we have analyzed the differential roles of IKKa and IKKb
in response to TNF in Hela cells (Figure 3). For this purpose we
have utilized siRNA to knockdown IKKa, IKKb and IKKa and
IKKb together in Hela cells. After 3 days of siRNA transfection,
knockdown of IKKa and of IKKb was highly effective. HeLa cells
were then treated with TNFa for the indicated times and NF-kB
activity was examined through analysis of IkB phosphorylation
and degradation. Importantly, kinetics of IkB phosphorylation and
degradation in IKKa and IKKb knock-down cells are both
impaired compared to control siRNA treated cells (Figure 3). For
instance, 5 min after TNF treatment, there is significant
degradation of IkBa in the control cells, while there is little or
no loss at that time point in the IKKa or IKKb knocked-down
cells. Additionally, phosphorylation of IkBa is reduced in the
IKKa and IKKb knockdown cells, which is more dramatic given
that there are elevated levels of IkBa in these cells at the 5 minute
time point. Degradation of IkBa is nearly lost with double-
knockdown (Figure 3). To determine the individual roles of IKKa
and IKKb in regulating NF-kB transcriptional activity, knock-
down experiments in HeLa cells were combined with transfection
of an NF-kB-dependent luciferase reporter (Figure 4). In response
to TNF treatment, IKKa and IKKb each contribute to NF-kB
transcriptional activity as measured through reporter assays
(Figure 4). These results indicate that IKKa contributes signifi-
Figure 1. The role of IKKa and IKKb in p65 phosphorylation and IkBa degradation in response to TNFa. MEF cells that are deficient for
IKKa, IKKb, or both IKKa and IKKb (DKO) were treated with TNFa for the indicated times. NF-kB activity, as measured by IkBa degradation and p65
phosphorylation, is diminished in IKKa and IKKb deficient MEF cells. IKKa and IKKb DKO cells show no detectable p65 phosphorylation. Tubulin levels
are shown as a loading control.
doi:10.1371/journal.pone.0009428.g001
IKKa in NF-kB Activation
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9428cantly to canonical NF-kB signaling, via control of IkBa
phosphorylation and degradation in HeLa cells with subsequent
transcriptional stimulation.
Knockdown of IKKa or IKKb Diminish TNF-Induced NF-kB
Activity in Breast Cancer Cells
To further analyze the roles of individual IKK kinases on NF-
kB activity and to analyze another cell type, we utilized siRNA
knockdown of IKKa, IKKb, and IKKa/b in SKBR3 breast
cancer cells (Figure 5). These cells were engineered to stably
express an NF-kB-dependent luciferase reporter. siRNA-transfect-
ed cells were either left untreated or were treated with TNF. As
shown in Figure 5, knockdown of IKKa significantly reduced NF-
kB dependent luciferase activity in response to TNF. Comparable
reduction was observed with IKKb knock-down. Importantly,
knockdown of IKKa and IKKb together further reduced the
luciferase activity in response to TNF. These results indicate that
both IKKa and IKKb are required for efficient TNF-induced NF-
kB activity in breast cancer cells.
Kinase Inactive IKKb Inhibits IKKa Activity
The data presented so far indicate that IKKa as well as IKKb
have significant roles in canonical NF-kB activation. Previous
results derived from expression of an IKKb kinase inactive mutant
have suggested that IKKb activity is highly dominant in canonical
NF-kB activation. In order to further examine this hypothesis, we
have utilized WT and IKKb KO MEF cells for transfection
studies. WT and IKKb 2/2 MEF cells were transfected with
empty vector or with an expression vector encoding IKKa along
with an NF-kB luciferase reporter plasmid. Results shown in Fig. 6
indicate that IKKa expression activates the NF-kB-dependent
reporter in both WT and IKKb 2/2 cells, consistent with a role
for IKKa in the canonical pathway and demonstrating that IKKa
can activate NF-kB in the absence of IKKb. Co-transfection of the
IKKa expression vector with low and higher levels of the IKKb
kinase inactive mutant demonstrates that the kinase inactive form
of IKKb blocks NF-kB-dependent reporter activity in WT and,
interestingly, in IKKb 2/2 cells. These findings demonstrate that
a kinase inactive version of IKKb inhibits the activity of IKKa.
TNF treatment of WT and IKKb 2/2 cells showed that cytokine
stimulation led to an approximate 4-fold increase in NF-kB-
dependent luciferase activity and this response was reduced to
approximately 2-fold with the loss of IKKb (Figure 6). This result
is consistent with the findings presented above for reporter activity
in cells knocked down for IKKa or IKKb, and indicate that IKKa
plays a key role driving NF-kB activity in the TNF-responsive
(canonical) pathway. Expression of the kinase inactive mutant of
IKKb strongly suppressed TNF-induced NF-kB activity in both
WT and IKKb 2/2 cells. These results further demonstrate that
the kinase inactive form of IKKb suppresses both IKKb as well as
IKKa activity. Therefore studies utilizing IKKb KM need to be
interpreted carefully as the effects observed from IKKb KM
expression will be derived from effects on both IKKb (as expected)
and IKKa (and see discussion). The results from these experiments
Figure 2. NF-kB DNA binding activity is reduced in IKKa and in
IKKb deficient cells. DNA binding activity of NF-kB was measured by
gel shift assay. Indicated MEF cells were treated with TNFa for indicated
times. Nuclear proteins were subject to gel shift assay for DNA binding
analysis.
doi:10.1371/journal.pone.0009428.g002
Figure 3. IKKa and IKKb knock-down in Hela cells leads to
diminished IkB degradation and p65 phosphorylation. HeLa
cells were grown in 6-well plates and transfected with the indicated
siRNA for 3 days. Western blots were performed on total cell extracts
after treatment with TNF for the indicated times. Tubulin levels are
shown as a loading control.
doi:10.1371/journal.pone.0009428.g003
IKKa in NF-kB Activation
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controlling NF-kB-activity in the canonical pathway.
Discussion
Based on the phenotypes of IKKa and IKKb animals, and on
results utilizing IKKa 2/2 and IKKb 2/2 MEFs, it has been
concluded that IKKb is the more important IKK catalytic subunit
relative to the control of NF-kB activation in the canonical
pathway [see 1–5]. Additionally, results using a kinase inactive
version of IKKb have supported these findings since expression of
this mutant strongly suppresses NF-kB activation in several cell
types. A variety of experiments have implicated NF-kB as a key
regulator of human cancer and of diseases associated with
inflammation [1–5]. Thus, interest in inhibiting NF-kB activation
has focused on the development of drugs that block IKKb. In fact,
IKKb inhibitors have shown efficacy in different models of disease
[25,26]. It is noted that blocking recruitment of IKKc (NEMO) to
the core IKK complex, which blocks canonical IKK activity, has
shown broad efficacy in animal models of inflammatory disorders
Figure 4. IKKa and IKKb each contribute to TNF-induced NF-kB activity in HeLa cells. HeLa cells, seeded in 24-well plates were transiently
transfected with indicated siRNA constructs for 48 hr. Then media was replaced and cells were further transfected with NF-kB responsive 3x-kB
luciferase and a control Renilla luciferase contructs. TNF was added (as indicated) and 24 hr later cells were lysed and dual lucifearse assay was
performed. Luciferase readings in untreated and control vector transfected cells were normalized as 1.
doi:10.1371/journal.pone.0009428.g004
Figure 5. Knockdown of IKKa or IKKb blocks basal and TNF-a induced NF-kB luciferase activity in breast cancer cells. SKBR3 cells
stably expressing 4x-kB firefly luciferase reporter gene were transfected with 100 nM siRNA against IKKa, IKKb or both. Cells were treated with PBS
(black) or 10 ng/ml TNF (gray striped) for 12 hr. Luciferase activity was measured and normalized to total protein levels.
doi:10.1371/journal.pone.0009428.g005
IKKa in NF-kB Activation
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IKKa (alone) or in combination with IKKb inhibition (via use of
distinct IKKa/IKKb inhibitors, or through blocking IKKc
interaction with the catalytic IKK components) will generate an
anti-inflammatory approach. Additionally, inhibiting IKKa alone
may have distinct advantages over inhibiting IKKb since IKKb
inhibition is associated with enhanced release of IL-1 [28].
Original data using knockout MEFs indicated that IKKb is the
critical kinase downstream of TNF in inducing IkBa phosphor-
ylation and degradation [see 13–15, 17–19]. While our data
completely agree with those results, loss of IKKa significantly
reduced NF-kB activation induced by TNF in MEFs as measured
through EMSA (Fig. 2) and reporter assays (Fig. 4–6). Addition-
ally, NF-kB-dependent reporter activity is only partly suppressed
in IKKb2/2 cells (Fig. 6), indicating the involvement of IKKa in
controlling NF-kB activity in MEFs. The mechanism of IKKa-
regulated NF-kB activation is unclear, but may involve the
phosphorylation response on p65 where IKKa is clearly involved
(see Fig. 1). For the IKKa-controlled pathway, phosphorylation of
p65 at ser536 may control DNA binding activity or release from
IkB. Interestingly, it was reported that phosphorylation of p65 at
ser536 does in fact induce release from IkB without degradation
[29]. Additionally, IKKa could potentially induce degradation of
IkBb or IkBe but our analysis did not reveal evidence of this
mechanism (data not shown). It has also been reported that IKKa
can control IKKb activity [30,31], which may contribute to TNF-
induced activity in wild-type cells but this cannot explain IKKa
activity in IKKb2/2 cells (Fig. 6). Future experiments will
address the specific effect whereby IKKa regulates NF-kB activity.
Based on the results obtained in MEFs, we extended our studies
to HeLa cells. Using siRNA knockdown of IKKa or IKKb in
these cells, we demonstrate that loss of either IKK subunit
suppresses IkBa phosphorylation, and delays IkB degradation (see
Fig. 3). These results indicate that in HeLa cells both IKKa and
IKKb are important for IkBa phosphorylation downstream of
TNF-induced signaling. The reason that IKKa is not involved in
IkBa phosphorylation/degradation in MEFs is unclear at the
present time, but is not related to lower relative levels of IKKa in
these cells, as determined by immunoblot analysis (see Fig. 1). To
analyze another cell type, we utilized SKBR3 human breast
cancer cells. Knockdown of IKKa or IKKb suppressed TNF-
induced NF-kB-dependent reporter levels (see Figs. 4 and 5), again
supporting the hypothesis that IKKa and IKKb are both
important for TNF-induced NF-kB activation.
We analyzed the effect of expression of a kinase-inactive form of
IKKb on NF-kB-driven reporter gene expression (see Fig. 6).
Previously, results derived from utilization of this mutant form of
IKKb havebeen usedtoargue theselectiveinvolvementofIKKb in
canonical signaling. IKKa expression in WT and in IKKb 2/2
cells induces NF-kB reporter activity, which is blocked by
expression of IKKb KM (Fig. 6). The ability of TNF to activate
the NF-kB-dependent luciferase reporter is only partly inhibited in
IKKb 2/2 cells, indicating the involvement of IKKa in the
response. Interestingly, expression of the IKKb kinase mutant
strongly suppresses TNF-induced reporter activity (below that seen
in IKKb 2/2 cells) and blocks TNF-induced in IKKb 2/2 cells,
indicating that the IKKb mutant blocks IKKa activity. Thus these
results indicate that IKKa is important in the NF-kB-dependent
gene expression response to TNF, and that the kinase inactive
IKKb blocks IKKa activity, potentially through engaging a key
regulatory molecule upstream of both IKKa and IKKb or through
dimerization with a wild-type IKK subunit and inhibition of the
IKK complex.
Why MEFs and HeLa cells appear to utilize IKKa and IKKb
differently regarding effects on IkBa phosphorylation is unclear.
This observation may indicate species differences or that different
cells/tissues utilize IKKa and IKKb differently, a concept that
should be considered in potential approaches to disease therapy.
This latter point may relate to different levels of key upstream
regulators of IKK. In this regard, it was reported that knockout of
IKKb in adult hepatocytes did not significantly suppress the ability
of TNF to activate NF-kB in these cells, with activity presumably
derived from IKKa [22]. This is in contrast to embryonic
RelA 2/2 or IKKb 2/2 hepatocytes which are sensitive to
TNF-induced killing due to poor activation of NF-kB. Also, this
group reported that IKK1/a and IKK2/b cooperate in the
canonical pathway in hepatocytes [32]. Furthermore, it was
reported that loss of IKKb leads to a compensatory activation of
Figure 6. IKKb kinase mutant inhibits TNF and IKKa-induced NF-kB-dependent reporter gene activity. WT and IKKb null MEFS were
transfected with the indicated vector construct and with the NF-kB-dependent luciferase reporter. Luciferase luciferase activity was measured 48 hr
after transfected. Where indicated, cells were treated with TNF for 4 hrs. Relative luciferase values were calculated using a renilla control expression
vector for normalization. Relative luciferase values are normalized to vector control samples.
doi:10.1371/journal.pone.0009428.g006
IKKa in NF-kB Activation
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suppression of NF-kB activity in our studies.
IKKb inhibitors have been developed and have shown
therapeutic responses in different animal models of diseases and
are in early clinical trials [25,26]. These inhibitors show significant
preference to IKKb over IKKa when tested against recombinant
proteins. The results presented here indicate that IKKa inhibitors
should be developed and tested using animal models of
inflammatory diseases. Additionally, the results indicate that dual
inhibition of IKKa/b would appear to be an optimal approach to
block NF-kB activity downstream of TNF and other inflammatory
cytokines [also see 33]. In summary, the data presented here
demonstrate that IKKa and IKKb are both functionally
important and cooperate in optimal TNF-induced (canonical)
NF-kB activation, with evidence that different cells may utilize
IKKa and IKKb differently.
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